BRCA2 and neoplasm: Median overall survival was nearly 3 years shorter for patients whose tumor(s) expressed BRCA2-001/Short (87 months, 95% CI 71.2–121) compared to those whose tumors did not (121 months, 95% CI 100.0–159).